Trial Profile
REVISE-Diabesity: Randomisation to Endoluminal intestinal liner alone Versus with Incretin analogue in SustainEd Diabesity
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Oct 2022
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Diabetes mellitus; Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REVISE-Diabesity
- 16 Sep 2016 Results of one year safety and efficacy evaluation (n=70) presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
- 25 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 17.
- 25 Apr 2016 Planned Primary Completion Date changed from 1 Jul 2016 to 1 Mar 17.